DDInter1613 DDInter1840
Rofecoxib is used for the treatment of osteoarthritis, rheumatoid arthritis, acute pain in adults, and primary dysmenorrhea, as well as acute treatment of migraine attacks with or without auras. Rofecoxib is a solid. This compound belongs to the stilbenes. These are organic compounds containing a 1,2-diphenylethylene moiety. Stilbenes (C6-C2-C6 ) are derived from the common phenylpropene (C6-C3) skeleton building block. The introduction of one or more hydroxyl groups to a phenyl ring lead to stilbenoids. Rofecoxib has a half-life of 17 hours and its mean oral bioavailability at therapeutically recommended doses of 125, 25, and 50 mg is approximately 93%. The proteins that rofecoxib target include elastin and prostaglandin G/H synthase 2
Trabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate _Ecteinascidia turbinata_ and now produced synthetically. Trabectedin has a unique mechanism of action. It binds to the minor groove of DNA interfering with cell division and genetic transcription processes and DNA repair machinery. It is approved for use in Europe, Russia and South Korea for the treatment of advanced soft tissue sarcoma. It is currently under evaluation for the treatment of breast cancer, prostate cancer, in addition to pediatric sarcomas. Both the European Commission and the U.S. Food and Drug Administration (FDA) have approved trabectedin as an orphan drug in soft tissue sarcomas and ovarian cancer. On October 23, 2015, the FDA approved trabectedin, (as Yondelis), for the treatment of specific soft tissue sarcomas.
Rofecoxib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Apixaban
Apixaban {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Trabectedin
Rofecoxib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gentamicin
Gentamicin {u} (Compound) causes {v} (Side Effect) Weight decreased
Weight decreased {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Rofecoxib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Treprostinil
Treprostinil {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Trabectedin
Rofecoxib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Treprostinil
Treprostinil {u} (Compound) causes {v} (Side Effect) Pulmonary embolism
Pulmonary embolism {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Rofecoxib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Metformin
Metformin {u} (Compound) upregulates {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Rofecoxib {u} may lead to a major life threatening interaction when taken with {v} Iohexol
Iohexol {u} (Compound) causes {v} (Side Effect) Hypersensitivity
Hypersensitivity {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Rofecoxib {u} may lead to a major life threatening interaction when taken with {v} Leflunomide
Leflunomide {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Trabectedin
Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Apixaban and Apixaban (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Trabectedin (Compound)
Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Gentamicin and Gentamicin (Compound) causes Weight decreased (Side Effect) and Weight decreased (Side Effect) is caused by Trabectedin (Compound)
Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Trabectedin (Compound)
Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil (Compound) causes Pulmonary embolism (Side Effect) and Pulmonary embolism (Side Effect) is caused by Trabectedin (Compound)
Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Metformin and Metformin (Compound) upregulates SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Rofecoxib may lead to a major life threatening interaction when taken with Iohexol and Iohexol (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Trabectedin (Compound)
Rofecoxib may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Trabectedin (Compound)